Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Combination of diphenhydramine and lorazepam, two centrally acting small molecule drugs. Diphenhydramine is a first-generation antihistamine that acts as an inverse agonist at the histamine H1 receptor, also antagonizes muscarinic acetylcholine receptors, and inhibits sodium channels. It is widely used for allergies, insomnia, and as an antiemetic and antiparkinson agent[4][7]. Lorazepam is a benzodiazepine that acts as a positive allosteric modulator at the GABA-A receptor, producing anxiolytic, sedative, anticonvulsant, and muscle relaxant effects[2][6][8]. The combination is not marketed under a unique brand name but has been studied experimentally for short-term treatment of insomnia and acute agitation, with reported increased sedation and risk of additive central nervous system depression[1][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on diphenhydramine + lorazepam.